Daewon Pharmaceutical
Launch date
Employees
Market cap
€238.5b
Enterprise valuation
€274m (Public information from Sep 2024)
Share price
KRW14600 003220.KQ
South Korea (HQ)
Financials
Estimates*
| KRW | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 309.0b | 354.0b | 479.0b | 527.0b | - | - | - |
| % growth | (3 %) | 15 % | 35 % | 10 % | - | - | - |
| EBITDA | 41.0b | 37.0b | 62.0b | 49.8b | - | - | - |
| % EBITDA margin | 13 % | 10 % | 13 % | 9 % | - | - | - |
| Profit | 19.0b | 7.0b | 31.0b | 23.9b | - | - | - |
| % profit margin | 6 % | 2 % | 6 % | 5 % | - | - | - |
| EV / revenue | 1.2x | 1.0x | 1.0x | 0.6x | - | - | - |
| EV / EBITDA | 9.3x | 9.3x | 7.5x | 6.7x | - | - | - |
| R&D budget | 13.5b | - | 12.6b | 9.0b | - | - | - |
| R&D % of revenue | 4 % | - | 3 % | 2 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
